뒤로
Opthea Limited(CKDXF) 가격
CKDXF 주가 차트
CKDXF 수입
Opthea Limited
$0.44
0%
$0
종가: Feb 06, 16:00:00 GMT-5
$0.44
0%
$0
애프터마켓: Feb 06, 20:00:00 GMT-5
최신 수익 결과: Q4 '25
보고됨: 2025-08-29
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
CKDXF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Opthea Limited CKDXF의 지난 분기 매출 실적은 어땠나요?
Opthea Limited의 매출 추정치는 얼마인가요?
Opthea Limited의 수익 품질 점수는 얼마인가요?
Opthea Limited는 언제 수익을 보고하나요?
Opthea Limited의 예상 수익은 얼마인가요?
Opthea Limited은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.44
시가
$0.29
일일 범위
$0.29 - $0.44
52주 범위
$0.29 - $0.44
거래량
130
평균 거래량
0
EPS(TTM)
-0.35
배당수익률
--
시가총액
$601.9M
OPTHEA LIMITED란 무엇인가요?
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development and research of novel therapeutic products based on targeting Vascular Endothelial Growth Factors. The company is headquartered in Melbourne, Victoria. The company is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. The company has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. The company is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.